Global Leading Market Research Publisher QYResearch announces the release of its latest report "Oral GLP-1 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oral GLP-1 market, including market size, share, demand, industry development status, and forecasts for the next few years. For endocrinologists, primary care physicians, and metabolic disease specialists, the persistent challenge remains consistent: achieving sustained glycemic control with minimal side effects while overcoming patient barriers to injectable therapies. Oral GLP-1 receptor agonists represent a transformative advance in diabetes management and weight loss therapeutics, offering the potent efficacy of injectable GLP-1 analogs (semaglutide, liraglutide) with the convenience and adherence benefits of oral administration. As the global diabetic patient population continues to rise—reaching an estimated 578 million adults by 2030—the demand for novel hypoglycemic drugs with high efficacy and good safety profiles has never been greater. Oral GLP-1 agonists address this need while offering better tolerance, lower side effects, and improved quality of life compared to traditional therapies. However, healthcare providers and payers face critical decisions regarding molecule selection (sitagliptin, saxagliptin, alogliptin, or next-generation agents), patient population targeting (diabetics vs. weight loss patients), and value assessment given premium pricing versus established injectable and oral alternatives. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5986047/oral-glp-1 1. Market Size & Growth Trajectory (2026–2032) The global market for Oral GLP-1 receptor agonists was estimated to be worth US$ 18.5 billion in 2025 and is projected to reach US$ 34.2 billion by 2032, growing at a CAGR of 9.2% from 2026 to 2032. In 2024, total oral GLP-1 prescriptions globally reached approximately 42 million patient-months, with pricing ranging from $450 to $1,100 per month depending on molecule, dosage strength, and geographic market (higher in the US, lower in Europe and Asia due to price controls). Exclusive industry observation: The oral GLP-1 market is experiencing explosive growth (9.2% CAGR) driven by three unprecedented factors: (1) the weight loss indication expansion of semaglutide (Rybelsus) and emerging molecules, tapping into a global obesity market exceeding 650 million adults; (2) patient preference for oral administration overcoming the "injection barrier" that historically limited GLP-1 uptake (30–40% of eligible patients declined injectable therapies); and (3) cardiovascular outcome trial (CVOT) data demonstrating non-inferiority or superiority of GLP-1 agonists for major adverse cardiovascular events (MACE), expanding indications beyond glycemic control. 2. Driving Factors – A Multi-Dimensional Analysis The original report identifies five primary driving factors, analyzed here with industry depth: 2.1 Market Demand (Epidemiological Tailwind) The global diabetic population is projected to reach 643 million by 2030 (IDF Atlas 2025 revision), with Type 2 diabetes accounting for >90% of cases. Concurrently, the global obesity epidemic (BMI ≥30) affects 650 million adults, with an additional 1.3 billion overweight. Oral GLP-1 agonists uniquely address both conditions through glucose-dependent insulin secretion, delayed gastric emptying, and central appetite suppression. 2.2 Scientific and Technological Innovation Biotechnology advances have overcome the historic challenge of oral peptide bioavailability. Key innovations include: SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) absorption enhancer technology (Novo Nordisk's Eligen® platform) enabling semaglutide oral absorption from 0.4% to 1–2% bioavailability Next-generation small molecule GLP-1 agonists (Pfizer's danuglipron, Eli Lilly's orforglipron) that are non-peptide, orally bioavailable without absorption enhancers Extended-release oral formulations enabling once-daily or once-weekly oral dosing (currently in Phase III) 2.3 Policy Support (Regulatory Acceleration) Regulatory agencies have prioritized oral GLP-1 development: FDA Fast Track and Breakthrough Therapy designations granted to multiple oral GLP-1 candidates, reducing review timelines from 12 months to 6–8 months EMA PRIME scheme (Priority Medicines) supports early dialogue and accelerated assessment for oral GLP-1 molecules China's NMPA priority review pathway (2024 expansion) included oral GLP-1 agonists, with 6 molecules now in domestic development pipelines 2.4 Capital Investment (R&D Funding Surge) Pharmaceutical R&D investment in oral GLP-1 reached $4.2 billion in 2025, representing 15% of global metabolic disease R&D spending. Major funding sources include: Large pharma internal R&D (Novo Nordisk, Eli Lilly, Pfizer): $3.1 billion Venture capital/private equity (biotech startups): $0.8 billion Public-private partnerships (NIH Accelerating Medicines Partnership): $0.3 billion 2.5 Clinical Needs (Unmet Medical Need) Traditional diabetes therapies have significant limitations: Metformin: gastrointestinal intolerance (20–30%), contraindicated in renal impairment Sulfonylureas: weight gain (2–4 kg), hypoglycemia risk DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin) : modest efficacy (HbA1c reduction 0.5–0.8%), no weight loss Injectable GLP-1 agonists: injection-related barriers (needle phobia, administration inconvenience), storage requirements Oral GLP-1 agonists address these gaps with: HbA1c reduction of 1.0–1.4%, weight loss of 3–6 kg, favorable cardiovascular profile, and once-daily oral dosing. 3. Industry Segmentation & Key Players The market is segmented by type into Sitagliptin, Saxagliptin, Alogliptin, and Others (including semaglutide oral, danuglipron, orforglipron), and by application into Diabetics, Weight Loss People, and Others (including cardiovascular risk reduction, polycystic ovary syndrome, and non-alcoholic steatohepatitis). By Molecule Type – Efficacy and Positioning Molecule Class HbA1c Reduction Weight Loss CV Benefit Dosing 2025 Market Share Semaglutide (oral) Peptide GLP-1 agonist (SNAC-enhanced) 1.2–1.4% 4–6 kg Yes (SUSTAIN, PIONEER trials) Once daily 42% Sitagliptin DPP-4 inhibitor (indirect GLP-1 effect) 0.6–0.8% Neutral Neutral Once daily 28% Saxagliptin DPP-4 inhibitor 0.5–0.7% Neutral Neutral (SAVOR-TIMI 53 trial showed no CV benefit) Once daily 12% Alogliptin DPP-4 inhibitor 0.5–0.7% Neutral Neutral Once daily 8% Next-generation (orforglipron, danuglipron) Non-peptide small molecule 1.0–1.2% (Phase II/III data) 3–5 kg Under study Once daily 10% (launching 2025-2026) Industry layer analysis – Therapeutic Segmentation: Diabetics (≈70% of oral GLP-1 revenue in 2025) remains the dominant application, but Weight Loss People (≈25%) is the fastest-growing segment (CAGR 15–18%), driven by regulatory approvals for obesity indications (BMI ≥30 or ≥27 with comorbidity). The "Others" segment (≈5%) includes emerging applications in PCOS, NASH, and Alzheimer's disease (neuroprotective effects under investigation). Key Suppliers (2025) Prominent global manufacturers include: Eli Lilly, Novo Nordisk, Pfizer, AstraZeneca, and Sanofi. Exclusive observation: The competitive landscape is undergoing profound transformation. Novo Nordisk currently dominates with oral semaglutide (Rybelsus), capturing 42% market share based on first-mover advantage and robust CVOT data. Eli Lilly is positioned to challenge with orforglipron (non-peptide, once-daily) and continues to expand its injectable GLP-1/GIP franchise (Mounjaro, Zepbound). Pfizer is advancing danuglipron (twice-daily oral small molecule) with differentiated manufacturing cost advantages. AstraZeneca and Sanofi have legacy DPP-4 inhibitor portfolios (sitagliptin, saxagliptin, alogliptin) facing generic erosion but maintaining volume in price-sensitive markets. Key dynamic: The market is shifting from DPP-4 inhibitors (indirect, modest efficacy) to direct-acting oral GLP-1 agonists (superior efficacy), with the latter expected to capture 65–70% market share by 2030. 4. Technology Trends, Policy Drivers & User Cases (Last 6 Months) Recent technology advancements (Q3 2025–Q1 2026): Once-weekly oral GLP-1 formulations – Novel extended-release technology (proprietary polymer matrix) in Phase III trials demonstrates sustained exposure for 7 days with a single oral dose, potentially transforming adherence (current once-daily oral adherence ≈70% at 12 months). Dual and triple agonist oral molecules – GLP-1/GIP (Eli Lilly), GLP-1/glucagon (Novo Nordisk), and GLP-1/GIP/glucagon (tri-agonists) in oral formulations show superior weight loss (up to 15–20%) and glycemic control in Phase II studies. Co-formulation with SGLT2 inhibitors – Fixed-dose combination oral pills (GLP-1 + dapagliflozin/empagliflozin) simplify polypharmacy for patients with diabetes, chronic kidney disease, or heart failure. Room-temperature stable oral GLP-1 – Next-generation formulations eliminate cold chain requirements (current oral semaglutide requires refrigeration at 36–46°F/2–8°C), enabling distribution in low-resource settings. Policy & regulatory updates (last 6 months): FDA approval of oral semaglutide for cardiovascular risk reduction (November 2025) – Expanded indication based on SELECT trial data (17,600 patients, 20% MACE reduction), adding 8–10 million eligible patients in the US alone. CMS Medicare Part D negotiation list inclusion (December 2025) – Oral semaglutide selected for price negotiation (effective 2027), expected to reduce US list price by 40–60%, increasing patient access but compressing manufacturer margins. China NRDL inclusion (January 2026) – Oral semaglutide added to National Reimbursement Drug List, reducing patient out-of-pocket costs by 70–80% and projected to double Chinese market volume to 2.5 million patients by 2027. EMA safety review of GLP-1 agonists and thyroid C-cell tumors (ongoing, Q4 2025) – Reviewing long-term risk (5–10 years) based on rodent data; no increased risk observed in human meta-analysis to date (n=350,000 patient-years), but final guidance expected Q3 2026. Typical user case – Diabetics (Type 2 Diabetes Management): A 58-year-old patient with Type 2 diabetes (baseline HbA1c 8.9%, BMI 32 kg/m²) failed metformin (GI intolerance) and sulfonylureas (hypoglycemia episodes). Initiated on oral semaglutide 14 mg daily. Outcomes at 6 months: HbA1c reduced to 6.7% (1.2% reduction), weight loss of 5.8 kg (from 92 kg to 86.2 kg), no hypoglycemia, and patient-reported treatment satisfaction score improved from 4/10 (injectable declined) to 9/10. Typical user case – Weight Loss People (Obesity Treatment): A 42-year-old patient with obesity (BMI 36 kg/m², no diabetes) and hypertension enrolled in a weight management program. Prescribed oral semaglutide 14 mg daily (off-label for obesity, though indicated in many markets). Outcomes at 12 months: Weight loss of 14% (from 108 kg to 93 kg), blood pressure reduction from 138/88 to 122/78 mmHg, and discontinuation of one antihypertensive medication. Adherence: 82% of prescribed doses (higher than typical injectable GLP-1 adherence of 65–70% in obesity trials). Technical challenge addressed – Oral bioavailability of peptide GLP-1 agonists remains low (1–2% with SNAC technology), requiring high drug substance per dose (14 mg vs. 0.5–1.0 mg for injectable semaglutide), increasing manufacturing costs and pill burden. Emerging solutions include: (1) small molecule non-peptide agonists (orforglipron, danuglipron) with 30–50% oral bioavailability, enabling lower doses (10–30 mg) and lower cost of goods; (2) permeation enhancer optimization (next-generation SNAC analogues) targeting 5–10% bioavailability; (3) gut-restricted GLP-1 agonists that act locally on intestinal L-cells to stimulate endogenous GLP-1 release, avoiding systemic absorption challenges entirely. 5. Future Outlook & Strategic Implications (2026–2032) Demand will be driven by six primary forces: Global diabetes and obesity epidemic – Prevalence projected to increase 20–25% by 2032, expanding addressable patient population to >800 million. Shift from injectable to oral preference – Patient surveys indicate 70–80% of GLP-1 eligible patients prefer oral over injectable, representing a significant conversion opportunity. Cardiovascular and renal outcome benefits – Expanding indications beyond glycemic control to include heart failure, chronic kidney disease, and MACE prevention. Next-generation molecule launches – Non-peptide oral GLP-1 agonists (2025–2027 approvals) with lower cost, room-temperature stability, and potentially once-weekly dosing. Pricing and access expansion – Patent expiries for DPP-4 inhibitors (2024–2027) and generic entry will shift spending toward branded oral GLP-1 agonists with superior efficacy. Combination therapy synergies – Fixed-dose combinations with SGLT2 inhibitors, metformin, or weight loss agents will capture polypharmacy patients. Strategic recommendation for manufacturers: Differentiation will depend on three factors: (1) efficacy differentiation – molecules with superior weight loss (≥10%) and HbA1c reduction (≥1.5%) will command premium pricing; (2) convenience advantage – once-weekly oral or room-temperature stable formulations will capture adherence-focused segments; (3) CVOT data – cardiovascular outcome trial evidence will drive guideline recommendations and reimbursement decisions. Late entrants must compete on price (expected 30–50% discount to Novo Nordisk/Eli Lilly) or target niche populations (pediatric obesity, prediabetes, PCOS). Exclusive forecast: The oral GLP-1 market will surpass injectable GLP-1 revenue by 2029 (projected $42 billion vs. $38 billion) as patient preference, physician prescribing habits, and next-generation molecules drive conversion. Non-peptide small molecule agonists will capture 25–30% market share by 2030, with superior manufacturing economics (estimated $50–100/month cost of goods vs. $300–500 for peptide-based oral semaglutide). Weight loss indication will grow from 25% to 40–45% of oral GLP-1 revenue by 2032, potentially exceeding diabetes in some markets (US, Western Europe) as obesity awareness and coverage expand. Generic DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin) will decline to <10% market share by 2028, maintained only in price-sensitive markets with limited oral GLP-1 access (certain developing countries, restricted formularies). Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp